Please join us for a 30-minute webinar on our new test for colorectal cancer screening: Occult Blood, CRC Screening.
The Fecal Immunochemical Test (FIT) screening method for hemoglobin in stool is the new standard of care for the early detection of blood which may be associated with colorectal cancer. It is changing the outcome of colorectal cancer.
We are offering two training webinars for our Spectrum Health and SHMG Providers and clinical staff on October 13th and 14th and two for our community providers and clinical staff (non-SHMG) on October 20th and 21st to help provide specific ordering practices.
The goal of this webinar is to address:
♦ Why screening for colorectal cancer is important.
♦ How to order to get supplies of the kit in your office.
♦ How to place the order.
♦ What is in the Polymedco FIT Kit.
♦ Patient collection process.
♦ Important instructions for the patient.
If you cannot attend one of the below webinars or have any questions, please use the Contact Us link above.
Mayo Clinic recently completed a four-year review of Myasthenia Gravis serum evaluations and will be implementing changes to our testing algorithm.
The Spectrum Health Lab Coagulation Department has the following changes that will be occurring on 1/12/21 as a result of new instrumentation:
As of February 12, 2020 testing for fecal calprotectin will be brought in-house.
As result Calprotectin, Feces (LAB3290) will be replaced with Calprotectin, Feces (LAB1230580).
Please note the following differences between the new and previous test in terms of specimen requirements and reference ranges.
Questions may be directed to the Toxicology Laboratory using the “Contact Us” link above.
Effective March 1, 2019, H. pylori IgG serologic testing will be discontinued as an orderable test at Spectrum Health Laboratory. This testing is no longer recommended by clinical guidelines.
Clinical guidelines no longer recommend serologic testing as a method for the diagnosis of H. pylori infection. Rather than IgG serology testing, other non-invasive testing methods such as H. pylori stool antigen and urea breath tests may be used to both diagnose and monitor response to therapy for H. pylori infection. In anticipation of an increase in stool antigen testing, currently a reference lab send-out test, Spectrum Health Regional Laboratory (SHRL) will be implementing this test as of October 29, 2018. By offering this test in-house, results will typically be available one day faster than present state.
On May 1, 2017, Spectrum Health Regional Laboratory adjusted the reference range for C-Reactive Protein (CRP) from ≤10 mg/L to ≤5.0 mg/L.
Spectrum Health Regional Laboratory is preparing to switch Clostridium difficile testing methods from solely using a molecular approach to a 2-step algorithm utilizing an Enzyme Immunoassay (EIA) that detects two C. difficile-specific proteins (glutamate dehydrogenase or GDH, and A/B toxin) with indeterminant EIA specimens reflexed to PCR (see flowchart below). It is estimated that approximately 90% of patients tested will be resolved by EIA and not require reflexive PCR testing. This algorithm decreases expenses to the patient by an average of 65% as compared to current testing without sacrificing result quality. Specimens will be batched for EIA testing at a frequency to ensure that results are available within 6 hours of receipt by the laboratory so that proper contact isolation precautions may be initiated when indicated.
As of January 30th, 2017 the test for Fecal Leukocytes will be discontinued and replaced with testing for Fecal Lactoferrin.
Effective August 18, 2016, the Spectrum Health Regional Laboratory Microbiology Department will begin offering the Verigene® Enteric Pathogens Test, a new rapid molecular test that simultaneously detects and identifies the following pathogenic enteric bacteria, viruses, and toxins that commonly cause acute community-acquired diarrhea. Testing occurs directly from stool in Cary-Blair preservative with a 1 day turnaround time (2-3 days faster than current methods).